Welcome to our dedicated page for Beyond Air SEC filings (Ticker: XAIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beyond Air, Inc. filings document the regulatory record for a commercial-stage nitric oxide medical device and biopharmaceutical company. Proxy materials cover stockholder votes on charter amendments, reverse stock-split authority, director elections, auditor ratification, and equity incentive plan share reserves.
Form 8-K disclosures record material events such as executive officer transitions, separation agreements, Nasdaq continued-listing compliance notices, annual meeting results, material agreements, capital-structure matters, operating and financial results, and clinical or regulatory disclosures tied to the company's nitric oxide programs.
Beyond Air, Inc. reported strong growth for its fiscal year ended March 31, 2026 and announced a change in fiscal year-end to December 31. Full-year revenue rose 107% to $7.7 million, while net loss narrowed to $33.2 million, or $4.01 per share, from $46.6 million.
For the March quarter, revenue increased 66% to $1.9 million and gross margin turned positive, but the company still recorded a quarterly net loss of $10.3 million. Operating expenses fell sharply year-over-year as research and development and general and administrative costs declined.
Beyond Air ended March 31, 2026 with $17.3 million in cash, cash equivalents, restricted cash and marketable securities and $21.6 million of total long-term debt. The company issued revenue guidance of $8 million for calendar 2026 and $16–$18 million for 2027, assuming commercial launch of its second-generation LungFit PH system.
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on nitric oxide (NO) technologies. Its LungFit® platform generates NO from ambient air for respiratory uses, led by LungFit® PH, which has FDA premarket approval for treating persistent pulmonary hypertension of the newborn and CE mark approval in Europe for broader pulmonary hypertension indications.
The company is commercializing LungFit® PH in the U.S., has regulatory approvals in more than 27 countries outside the U.S. and EU, and distribution agreements covering over 40 countries. Pipeline devices include LungFit® PRO for viral pneumonias and bronchiolitis, and LungFit® GO for nontuberculous mycobacterial lung infections, all using high-concentration NO to target infections. Beyond Air’s majority-owned affiliate Beyond Cancer is developing ultra-high concentration NO (UNO) for solid tumors, having completed a Phase 1 trial, while NeuroNOS is advancing selective nNOS inhibitors for autism spectrum disorder and glioblastoma, with two FDA orphan drug designations. The company’s auditor has expressed substantial doubt about its ability to continue as a going concern, and management highlights the need for additional capital and strict compliance with its loan agreement.
Beyond Air, Inc. stockholders approved giving the board discretion to implement a reverse stock split within a range of 1-for-2 to 1-for-20, with no change to authorized share counts. At the June 18, 2026 special meeting, 5,177,506 votes were cast in favor, 1,222,793 against and 87,461 abstained, from 12,692,684 shares outstanding as of the April 20, 2026 record date.
Immediately after the vote, the board approved a specific 1-for-20 reverse split ratio, combining every 20 outstanding shares of common stock into one share, to be effected after a certificate of amendment becomes effective. The company states it intends to use the split to increase its share price above $1.00 for at least ten trading days to regain compliance with Nasdaq Listing Rule 5550(a)(2) by July 31, 2026, while cautioning there is no assurance the split will be implemented as planned or achieve the desired effects.
Beyond Air, Inc. received a decision from a Nasdaq Hearings Panel granting its request to continue listing on The Nasdaq Stock Market, provided it regains compliance with Nasdaq Listing Rule 5550(a)(2), the Bid Price Rule, by July 31, 2026. The company remains compliant with all other Nasdaq continued listing requirements.
Once Beyond Air regains bid price compliance, it will be subject to a one-year Discretionary Panel Monitor period. If it fails any Nasdaq listing standard during that year, Nasdaq staff will issue a delisting determination without allowing a new compliance plan. Shareholders are scheduled to vote on a reverse stock split proposal at a special meeting on June 18, 2026, which the company expects could help it meet the bid price requirement.
Beyond Air, Inc. Schedule 13G/A: Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh report 0 shares beneficially owned of Common Stock (CUSIP 08862L202), representing 0.00% of the class. The filing is a joint amendment pursuant to Rule 13d-1(k).
The cover shows an amendment dated 03/31/2026 and signatures dated 05/15/2026. The filers state ownership is five percent or less of the class and list their principal office at 77 West Wacker Drive, Chicago, IL.
Balyasny Asset Management and related entities report beneficial ownership of 763,266 shares of Beyond Air, Inc. Common Stock, representing approximately 7.25% of the class. The total includes 299,104 shares issuable upon exercise of Warrants subject to a Beneficial Ownership Limitation that restricts exercises above 9.99%. The 10,529,344 Shares outstanding as of February 10, 2026 is cited as the basis for the percentage. The ownership is held on behalf of Atlas Diversified Master Fund, Ltd. and disclosed through BAM, BAM GP, BAM Holdings, Dames, and Dmitry Balyasny.
Beyond Air, Inc. is calling a special stockholder meeting on June 18, 2026 to approve a reverse stock split of its common stock at a ratio between 1-for-2 and 1-for-20, at the Board’s discretion, and to approve a related adjournment proposal.
The company received a Nasdaq notice on April 7, 2026 for failing the $1.00 minimum bid price requirement, after its shares traded below $1.00 for 30 consecutive business days. Because it previously completed a 1-for-20 reverse split on July 14, 2025, it is not eligible for the standard compliance period and faces potential delisting unless a Nasdaq Hearings Panel grants continued listing.
The Board views the reverse split as a way to raise the share price to meet Nasdaq rules and support future capital raising. As of the April 20, 2026 record date, there were 12,692,684 shares of common stock outstanding, each entitled to one vote at the meeting.
Beyond Air, Inc. (XAIR) is asking shareholders to approve a Fourth Amendment to its charter that would permit the Board, within one year, to implement a reverse stock split of Common Stock at a ratio between 1-for-2 and 1-for-20 (Proposal 1). The company reported 13,192,684 shares outstanding as of the April 20, 2026 record date and disclosed the last reported sale price was $0.5450, below Nasdaq’s $1.00 minimum bid requirement. The Board states it intends to effect the reverse split if needed to address Nasdaq noncompliance, subject to Board discretion and market conditions. A second proposal seeks authority to adjourn the Special Meeting to solicit additional proxies if votes are insufficient (Proposal 2). The Special Meeting is scheduled for June 18, 2026.
Beyond Air, Inc. has received written notice from Nasdaq that its common stock is not in compliance with the $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2), which is required for continued listing.
The company has requested a hearing before the Nasdaq Hearings Panel, which has been scheduled for May 14, 2026. This timely request stays any suspension or delisting action until the Panel issues a written decision, so the stock is expected to remain listed on Nasdaq during the hearing process.
The company cautions that there is no assurance the Panel will grant continued listing or that it will regain compliance with Nasdaq’s continued listing standards, and it includes forward-looking statement disclaimers referencing risks described in its Form 10-K and other SEC filings.
Beyond Air, Inc. reported that it received a Nasdaq notice on April 7, 2026 stating its common stock no longer meets the minimum $1.00 per-share bid price required by Nasdaq Listing Rule 5550(a)(2). The deficiency was triggered because the stock’s closing bid price stayed below $1.00 for thirty consecutive business days from February 23, 2026 to April 6, 2026, which violates the Bid Price Rule.
Because the company previously effected a 1-for-20 reverse stock split on July 14, 2025, Nasdaq rules make it ineligible for the usual 180-day cure period. As a result, its securities are subject to delisting unless it requests a hearing with the Nasdaq Hearings Panel by April 14, 2026. Beyond Air plans to request this hearing, which would automatically stay any suspension or delisting while the Panel reviews the case. During this appeal process, the stock is expected to continue trading on Nasdaq.
The company says it will closely track its bid price and is considering options to regain compliance with Nasdaq’s listing standards, including potentially using another reverse stock split. However, it cautions there is no assurance the Panel will grant continued listing or that compliance can be regained and maintained, underscoring a meaningful risk around its Nasdaq listing status.